Hope for rare cancers: new immunotherapy combo tested in nationwide trial

NCT ID NCT06790706

First seen Nov 01, 2025 · Last updated Jun 08, 2026 · Updated 29 times

Summary

This study tests a combination of two immunotherapy drugs (domvanalimab and zimberelimab) in people with five types of rare advanced cancers that have not responded to standard treatment. The goal is to see if this treatment can shrink tumors or stop them from growing for at least 24 weeks. About 154 participants will receive the drugs and be monitored for side effects and disease progression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • AP-HM, TIMONE Hospital, medical oncology department

    NOT_YET_RECRUITING

    Marseille, 13009, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • AP-HP, Tenon Hospital, medical oncology department

    NOT_YET_RECRUITING

    Paris, 75020, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Centre Eugène Marquis, medical oncology department

    NOT_YET_RECRUITING

    Rennes, 35042, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Centre Hospitalier Universitaire de Lille, medical oncology department

    NOT_YET_RECRUITING

    Lille, 59037, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Hospices Civils de Lyon, Medical Oncology Department, Edouard Herriot Hospital

    RECRUITING

    Lyon, 69003, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Hospices Civils de Lyon, Medical Oncology Department, Lyon SUD Hospital

    RECRUITING

    Pierre-Bénite, 69310, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Hospices Civils de Lyon, Thoracic Oncology Department, Louis Pradel Hospital

    RECRUITING

    Bron, 69500, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Insitut de Cancérologie Strasbourg Europe, medical oncology department

    NOT_YET_RECRUITING

    Strasbourg, 67200, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Institut Bergonié, medical oncology department

    NOT_YET_RECRUITING

    Bordeaux, 33076, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Institut Curie, thoracic oncology department

    NOT_YET_RECRUITING

    Paris, 75005, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Institut Gustave Roussy, medical oncology department

    NOT_YET_RECRUITING

    Villejuif, 94805, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Institut Paoli-Calmettes Marseille, medical oncology department

    NOT_YET_RECRUITING

    Marseille, 13009, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Institut Régional du Cancer de Montpellier, medical oncology department

    NOT_YET_RECRUITING

    Montpellier, 34298, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Institut de Cancerologie de l'Ouest , medical oncology department

    NOT_YET_RECRUITING

    Angers, 49055, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • ONCOPOLE Claudius Regaud, IUCT-Oncopole, medical oncology department

    NOT_YET_RECRUITING

    Toulouse, 31059, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.